Estracyt® in Advanced Prostatic Carcinoma: Case Report

Publisher Website
Google Scholar
Abstract
A 75-year-old man with metastasising prostatic carcinoma was treated with Estracyt® (estradiol-3-N[bis-(2-chlorethyl)]-carbamate-17-dihydrogen phosphate). Histological and cytological examination showed complete regression of some lymph node metastases. Renographic and roentgen examinations revealed regression of other lymph node metastases. The patient felt better, his general condition improved and the indwelling catheter could be removed. Treatment was continued for 2 months during which the patient received a total of 9.5 g Estracyt® i.v. No side effects were observed.